{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:36:11Z","timestamp":1707525371090},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,31]]},"DOI":"10.7759\/cureus.48065","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T22:18:15Z","timestamp":1698790695000},"source":"Crossref","is-referenced-by-count":0,"title":["Dosing Challenges and Benefits of Vericiguat in a Patient With Decompensated Heart Failure: A Case Report"],"prefix":"10.7759","author":[{"given":"Mario","family":"Speranza-S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esteban","family":"Zavaleta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Sancho-Zumbado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Elizondo-Urrutia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alonso","family":"Quir\u00f3s-Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Chaverri-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Garc\u00eda-Montero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebasti\u00e1n","family":"Arguedas-Chac\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Heart failure with reduced ejection fraction","volume":"77","author":"Riello III RJ","year":"2021","unstructured":"Riello III RJ. Heart failure with reduced ejection fraction. Cardiology. 2021, 77:772-810.","journal-title":"Cardiology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.10262","article-title":"Heart failure with reduced ejection fraction: a review","volume":"324","author":"Murphy SP","year":"2020","unstructured":"Murphy SP, Ibrahim NE, Januzzi JL Jr. Heart failure with reduced ejection fraction: a review. JAMA. 2020, 324:488-504. 10.1001\/jama.2020.10262","journal-title":"JAMA"},{"key":"ref3","article-title":"National registry of heart failure in Costa Rica. The RENAIC CR study","volume":"19","author":"Speranza S\u00e1nchez MO","year":"2017","unstructured":"Speranza S\u00e1nchez MO, Quesada Chaves D, Castillo Chaves G, et al.. National registry of heart failure in Costa Rica. The RENAIC CR study. Rev Costarric Cardiol. 2017, 19:21-34.","journal-title":"Rev Costarric Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2016.04.054","article-title":"Burden of heart failure in Latin America: a systematic review and meta-analysis","volume":"69","author":"Ciapponi A","year":"2016","unstructured":"Ciapponi A, Alcaraz A, Calder\u00f3n M, Matta MG, Chaparro M, Soto N, Bardach A. Burden of heart failure in Latin America: a systematic review and meta-analysis. Rev Esp Cardiol (Engl Ed). 2016, 69:1051-60. 10.1016\/j.rec.2016.04.054","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong PW","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, et al.. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020, 382:1883-93. 10.1056\/NEJMoa1915928","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S357422","article-title":"Vericiguat in heart failure with a reduced ejection fraction: patient selection and special considerations","volume":"18","author":"Kassis-George H","year":"2022","unstructured":"Kassis-George H, Verlinden NJ, Fu S, Kanwar M. Vericiguat in heart failure with a reduced ejection fraction: patient selection and special considerations. Ther Clin Risk Manag. 2022, 18:315-22. 10.2147\/TCRM.S357422","journal-title":"Ther Clin Risk Manag"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jccase.2022.08.012","article-title":"Initial experience of vericiguat add-on therapy upon fantastic four medical therapy in a patient with systolic heart failure","volume":"26","author":"Imamura T","year":"2022","unstructured":"Imamura T, Kinugawa K. Initial experience of vericiguat add-on therapy upon fantastic four medical therapy in a patient with systolic heart failure. J Cardiol Cases. 2022, 26:429-31. 10.1016\/j.jccase.2022.08.012","journal-title":"J Cardiol Cases"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-020-07099-2","article-title":"Relative efficacy of sacubitril-valsartan, Vericiguat, and SGLT2 inhibitors in heart failure with reduced ejection fraction: a systematic review and network meta-analysis","volume":"35","author":"Aimo A","year":"2021","unstructured":"Aimo A, Pateras K, Stamatelopoulos K, et al.. Relative efficacy of sacubitril-valsartan, Vericiguat, and SGLT2 inhibitors in heart failure with reduced ejection fraction: a systematic review and network meta-analysis. Cardiovasc Drugs Ther. 2021, 35:1067-76. 10.1007\/s10557-020-07099-2","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2020.08.008","article-title":"N-terminal pro-B-type natriuretic peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study","volume":"8","author":"Ezekowitz JA","year":"2020","unstructured":"Ezekowitz JA, O'Connor CM, Troughton RW, et al.. N-terminal pro-B-type natriuretic peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study. JACC Heart Fail. 2020, 8:931-9. 10.1016\/j.jchf.2020.08.008","journal-title":"JACC Heart Fail"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd10090388","article-title":"Vericiguat: The Fifth Harmony of heart failure with reduced ejection fraction","volume":"10","author":"Falco L","year":"2023","unstructured":"Falco L, Brescia B, Catapano D, et al.. Vericiguat: The Fifth Harmony of heart failure with reduced ejection fraction. J Cardiovasc Dev Dis. 2023, 10:10.3390\/jcdd10090388","journal-title":"J Cardiovasc Dev Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/HCQ.0000000000000102","article-title":"2021 ACC\/AHA key data elements and definitions for heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on clinical data standards (writing committee to develop clinical data standards for heart failure)","volume":"14","author":"Bozkurt B","year":"2021","unstructured":"Bozkurt B, Hershberger RE, Butler J, et al.. 2021 ACC\/AHA key data elements and definitions for heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on clinical data standards (writing committee to develop clinical data standards for heart failure). Circ Cardiovasc Qual Outcomes. 2021, 14:e000102. 10.1161\/HCQ.0000000000000102","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"145","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al.. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022, 145:e895-e1032. 10.1161\/CIR.0000000000001063","journal-title":"Circulation"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2221","article-title":"Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial","volume":"23","author":"Voors AA","year":"2021","unstructured":"Voors AA, Mulder H, Reyes E, et al.. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial. Eur J Heart Fail. 2021, 23:1313-21. 10.1002\/ejhf.2221","journal-title":"Eur J Heart Fail"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/200108-dosing-challenges-and-benefits-of-vericiguat-in-a-patient-with-decompensated-heart-failure-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:08:56Z","timestamp":1707509336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/200108-dosing-challenges-and-benefits-of-vericiguat-in-a-patient-with-decompensated-heart-failure-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,31]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.48065","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,31]]}}}